Cases
Representative Matters: Public Offerings: Represented BG Medicine, Inc. (Nasdaq: BGMD) in its $40 million initial public offering
Represented Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) in over $1 billion in various equity
debt public offerings
Represented ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) in its $258 million follow-on public offering
other public offerings
Represented Synta Pharmaceuticals Corp. (Nasdaq: SNTA) in its $35 million equity line facility with Azimuth Opportunity Ltd.
Represented Myriad Genetics, Inc. (Nasdaq: MYGN) in its $105 million follow-on public offering
other public offerings
Mergers & Acquisitions: Represented Ember Corporation in its $72 million acquisition by Silicon Laboratories Inc. (SLAB)
Represented Myriad Genetics, Inc. (Nasdaq: MYGN) in its $80 million acquisition of Rules-Based Medicine, Inc.
Represented Arbinet Corporation (Nasdaq: ARBX) in its acquisition by Primus Telecommunications Group, Inc. (NYSE: PTGI)
Represented ION Torrent Systems Incorporated in its $725 million acquisition by Life Technologies Corporation (Nasdaq: LIFE)
Represented Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) in its $300+ million (cash
stock) acquisition of ViroChem Pharma, Inc.
Represented iBasis, Inc. (Nasdaq: IBAS) in it $100 million sale to Royal KPN, NV
Represented ClariFI, Inc. in its acquisition by St
ard & Poor's, a division of the Mc-Graw Hill Companies (NYSE: MHP) (undisclosed amount)
Represented Netonomy, Inc. in its $19 million acquisition by Comverse Technology, Inc. (Nasdaq: CMVT)
Venture Capital Financings: Represented Pulmatrix, Inc. in various preferred stock
convertible debt financings
in general corporate matters
Represented BG Medicine, Inc. (BGMD) in its $40 million Series D financing
in general corporate matters
Represented Virtify, Inc. in various preferred stock financings
in general corporate matters
Represented Ember Corporation in various preferred stock
convertible debt financings
in general corporate matters
Represented Allegro Diagnostics Corp. in various convertible debt financings
in general corporate matters
